Watch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
Tag Archive for: inclusion body myositis
RDMD and MSU Collaborating for IBM Research
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
We are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
During Myositis Awareness Month, May 2018, we placed a large focus on patient education by hosting some of the...
EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Clinical trials and studies require patient groups in clearly defined categories, but the multiple diagnostic and classification criteria used...
Advances in the Early Diagnosis and Therapy of Inclusion Body Myositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
The purpose of this article is to describe advancements in the diagnosis of Inclusion Body Myositis (IBM) and therapy...
MSU and Orphazyme: Working together for a treatment for inclusion body myositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Updated April 23, 2019 - Study is fully enrolled. One of our goals is to provide inclusion body...
New Study for Patients with Inclusion Body Myositis (IBM) at Yale
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
We would like to let you know about a clinical research study that is available for patients diagnosed with...
New Insights on sporadic Inclusion body myositis (sIBM) pathogenesis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Dr. Conrad "Chris" Weihl joins MSU live for a session titled "New Insights on sporadic Inclusion body myositis (sIBM)...
The NT5C1A Antibody Test and its Role in the Diagnosis of Inclusion Body Myositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Learn more about the NT5CIA antibody and its association with inclusion body myositis from Dr. Kevin Dooley, a retired...
Orphazyme formally assumes the sponsorship of Phase II/III arimoclomol trial for sIBM
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme formally assumes the...
A touching personal story from the daugher of a myositis patient remembering that her Dad, her longtime hero, ...
FDA grants Orphazyme drug arimoclomol orphan drug designation in the U.S.
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Orphazyme A/S, a Danish biotech company with a late-stage orphan drug pipeline, today announced that the U.S. Food and...
Sadly, my mum lost her battle as an IBM warrior
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Mums journey was a very difficult one. I remember her first fall the day I gave birth to...
Maureen Hume shares her experiences living with Inclusion Body Myositis, staring years before her diagnosis.